Table 2 Baseline patient demographics and disease characteristics of the integrated double-blind studies
Galcanezumab | |||
|---|---|---|---|
Placebo N = 1451 n (%) | 120 mg N = 705 n (%) | 240 mg N = 730 n (%) | |
Age | |||
< 30 years | 269 (18.5) | 139 (19.7) | 158 (21.6) |
≥ 30 and < 40 years | 342 (23.6) | 182 (25.8) | 194 (26.6) |
≥ 40 and < 50 years | 435 (30.0) | 199 (28.2) | 192 (26.3) |
≥ 50 years | 405 (27.9) | 185 (26.2) | 186 (25.5) |
Sex | |||
Male | 214 (14.8) | 106 (15.0) | 121 (16.6) |
Female | 1237 (85.3) | 599 (85.0) | 609 (83.4) |
Race | |||
American Indian or Alaska Native | 24 (1.7) | 10 (1.4) | 16 (2.2) |
Asian | 89 (6.1) | 48 (6.8) | 42 (5.8) |
Black or African American | 117 (8.1) | 53 (7.5) | 59 (8.1) |
Native Hawaiian, Other Pacific Islander | 2 (0.1) | 0 (0.0) | 4 (0.6) |
White | 1112 (76.6) | 545 (77.3) | 555 (76.1) |
Multiple | 107 (7.4) | 49 (7.0) | 53 (7.3) |
Ethnicity | |||
Hispanic or Latino | 298 (20.5) | 149 (21.1) | 170 (23.3) |
Not Hispanic or Latino | 1077 (74.2) | 522 (74.0) | 530 (72.6) |
Region | |||
North America | 977 (67.3) | 472 (67.0) | 496 (68.0) |
Europe | 262 (18.1) | 126 (17.9) | 131 (18.0) |
Other | 212 (14.6) | 107 (15.2) | 103 (14.1) |
Comorbid conditions occurring in > 10% of any dose-group | |||
Seasonal allergy | 307 (21.2) | 158 (22.4) | 122 (16.7)a |
Drug hypersensitivity | 247 (17.0) | 123 (17.5) | 128 (17.5) |
Insomnia | 165 (11.4) | 89 (12.6) | 78 (10.7) |
Anxiety | 166 (11.4) | 82 (11.6) | 81 (11.1) |
Depression | 181 (12.5) | 84 (11.9) | 79 (10.8) |
Back pain | 151 (10.4) | 62 (8.8) | 75 (10.3) |
Cardiovascular disease risk groupb | |||
Yes | 269 (18.5) | 123 (17.5) | 124 (17.0) |
No | 1182 (81.5) | 582 (82.6) | 606 (83.0) |